Eric Warren, Chief Commercial Officer at Esperion Therapeutics, Inc. (ESPR), sold 107 shares at $2.12 ($227) on 2024-10-17, disclosed to the SEC on 2024-10-18.
Open-market sale of $227 ESPR by Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| MLYS | SELL | 2026-07-23 | $200K | — | Filing → |
| MLYS | SELL | 2026-06-30 | $2.7M | — | Filing → |
| ESPR | SELL | 2025-04-21 | $106 | — | Filing → |